ArticleAdvances in therapy2026

Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.

Nieves Lopez-Muñoz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.